Decision IntelBiogen
Biogen Aduhelm Approval Controversy
Estimated impact: $11B market cap loss when CMS restricted coverage; institutional credibility damage
The FDA approved Biogen's Alzheimer's drug Aduhelm via accelerated approval despite an advisory committee voting nearly unanimously against it. The $56,000/year drug showed no clear clinical benefit. Three advisory committee members resigned in protest. CMS later restricted coverage.
Decision context
Whether the FDA should have approved a drug that failed two Phase III trials and whose advisory committee voted 10-0 (with 1 uncertain) against approval.
What the company’s own filing already carried
Not our reading of a memo. Biogen's own 10-K, filed 2020-02-06 (11 months before the 2021 decision), was read by the audit engine's deterministic structural layer: the same detectors that run on every audit, with no language model involved. Everything below is drawn from the company's own disclosure, before any knowledge of what followed, and never from the decision itself.
Survivable as structured: if the flagged risk fires, the deal has the exits, cushions, or staging to absorb the hit and continue.
The structural layer flagged no unabsorbed condition in this filing.
- This reads the company's own 10-K (filed 11 months before the decision), not the decision memo itself, so it can only understate what a full audit of the memo would surface.
- It reads the structure of the situation, not the trigger: whether a shock to the flagged conditions would be absorbed, never that a shock arrives.
- A reading of a dated filing, not a prediction: every condition can be checked against the company's own 10-K.
Decision anatomy
Red = risk factor present · Green = protective factor present
Biases present in the decision
★ Primary driver · Severity estimated from bias type and decision outcome
Toxic combinations
The curated library this case sits in
Across all 155 curated case studies in our library, by documented outcome:
The library is curated toward documented failures, so this split describes the library, not the base rate of deals. The case above is one row in it.
Lessons learned
- Optimism bias in Alzheimer's research created pressure to approve any drug showing a biomarker effect regardless of clinical outcomes
- Overriding an advisory committee's near-unanimous rejection damages the credibility of the regulatory process
- Accelerated approval based on surrogate endpoints (amyloid reduction) when clinical benefit is unproven sets a dangerous precedent
Source: FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting transcript (2020); STAT News investigation (2021) (FDA Action)
These patterns were flaggable in Biogen's own record — before the outcome.
See the full reasoning audit we ran — no login, no card. Then run the same audit on a deal you have already closed.
Or leave your email, we'll run the audit on a deal of your choosing and send the readout within a business day.
Workflows that fire on decisions like Biogen’s
The same Recognition-Rigor Framework that documents this case audits memos in the same shape — before the outcome forces the lesson.